| Significant Segment Expenses |
Significant segment expenses, as provided to the CODM, are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30,
|
|
|
Six Months Ended June 30,
|
|
|
|
|
2026
|
|
|
2025
|
|
|
2026
|
|
|
2025
|
|
|
Sales
|
|
$
|
331,827 |
|
|
|
409,268 |
|
|
|
756,716 |
|
|
|
750,532 |
|
|
Cost of sales (excluding depreciation expense)
|
|
|
142,436 |
|
|
|
158,171 |
|
|
|
301,042 |
|
|
|
275,437 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expense
|
|
|
616,014 |
|
|
|
89,217 |
|
|
|
1,054,814 |
|
|
|
1,048,380 |
|
|
Other research and development expense1
|
|
|
1,330,864 |
|
|
|
1,325,212 |
|
|
|
2,201,465 |
|
|
|
3,334,521 |
|
|
Total research and development expense
|
|
|
1,946,878 |
|
|
|
1,414,429 |
|
|
|
3,256,279 |
|
|
|
4,382,901 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales and marketing expense
|
|
|
1,293,998 |
|
|
|
984,977 |
|
|
|
2,609,753 |
|
|
|
1,893,544 |
|
|
General and administrative expense
|
|
|
1,931,578 |
|
|
|
1,616,972 |
|
|
|
3,713,968 |
|
|
|
3,339,685 |
|
|
Depreciation and amortization expense
|
|
|
82,811 |
|
|
|
86,285 |
|
|
|
165,081 |
|
|
|
171,138 |
|
|
Total operating expenses
|
|
|
5,255,265 |
|
|
|
4,102,663 |
|
|
|
9,745,081 |
|
|
|
9,787,268 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income (expense), net
|
|
|
597,644 |
|
|
|
(734,356 |
)
|
|
|
5,667,277 |
|
|
|
(1,174,776 |
)
|
|
Loss before income taxes
|
|
|
(4,468,230 |
)
|
|
|
(4,585,922 |
)
|
|
|
(3,622,130 |
)
|
|
|
(10,486,949 |
)
|
|
Income tax expense (benefit)
|
|
|
865 |
|
|
|
— |
|
|
|
865 |
|
|
|
(4,188 |
)
|
|
Net loss
|
|
|
(4,469,095 |
)
|
|
|
(4,585,922 |
)
|
|
|
(3,622,995 |
)
|
|
|
(10,482,761 |
)
|
1 Other research and development expense include clinical affairs, regulatory, manufacturing and quality assurance expenses.
|